Saleha Patel
Pipeline & Commercialisation Strategy Head Constructive Bio
Dr Saleha Patel joined Constructive Bio in early 2025 bringing over a decade of experience from large pharma. In her previous role within the Emerging Innovations Unit at AstraZeneca she led indication discovery and expansion activities for pipeline assets, leveraging cutting-edge AI and multi-omics approaches to generate novel disease hypotheses. Her role also involved catalysing new and transformative areas of science and technology and supporting the global early-stage innovation ecosystem. Prior to joining AstraZeneca, Saleha carried out her PhD and postdoctoral studies in biochemistry and structural biology at the University of Leicester in partnership with UCB Pharma. She currently holds Board and external leadership positions in a number of organisation including ELRIG UK, Nature Scientific Reports, The Sutton Trust and is an honorary lecturer at Queen Mary University of London.
Seminars
- Broadening the therapeutic scope of GLP-1s as the new frontier for a wide range of new applications, such as cardiovascular disease, neurodegenerative disorders and ageing, offering patients a more comprehensive approach to health beyond just weight loss
- Enhancing drug delivery for patient success to improve patient adherence through less frequent administration, including once-a-month injections and oral medications, providing a convenient and less intrusive treatment experience that supports longterm adherence
- Integrating a complementary ecosystem of care for collaborative approach of chronic drugs, advanced combinations, and procedural solutions that work together to create a personalized treatment plan for each patient, maximizing chances of achieving sustainable metabolic health
- Utilizing genetic code expansion and engineered translation for the incorporation of non-canonical amino acids (ncAAs) for creating new-to-nature biotherapeutics; enabling drug candidates with improved stability, efficacy, and novel mechanisms of action beyond traditional incretin agonism
- Exploring how sustainable biomanufacturing is strategically important to overcome the high cost and inefficiency of existing chemical peptide synthesis methods, ensuring that next-generation peptide therapeutics can meet massive global demand at partner-grade quality and industry-scale titres
- Prioritizing platform technologies in commercialization strategies that enable rapid, cost-effective scale-up and yield differentiated value, moving the field past dose-optimization of existing drugs toward wholly novel, patient-focused treatments
